ArticleActa pharmaceutica Sinica. B2023

Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood-brain barrier and exhibits potent activity against glioblastoma.

Yingqiang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.